<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216436</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00019239</org_study_id>
    <nct_id>NCT01216436</nct_id>
  </id_info>
  <brief_title>Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma</brief_title>
  <official_title>Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our proposed study is designed to test the safety of a new vaccine against melanoma. The&#xD;
      induction of immune activity against cancers such as melanoma is a promising approach to&#xD;
      cancer treatment, but to date, only a few clinically significant immune responses have been&#xD;
      seen following vaccine therapy. This is an important problem, since there are very limited&#xD;
      treatment options for patients with metastatic melanoma (melanoma that has spread to lymph&#xD;
      nodes and organs).&#xD;
&#xD;
      Studies suggest that monoclonal antibodies (mAbs) that block inhibitory receptors on immune&#xD;
      cells can enhance the immune responses against cancer, but the intravenous injection of such&#xD;
      mAbs has caused severe side effects in animals and humans. In our laboratory, we have&#xD;
      developed a method to deliver mAbs and other proteins that block such inhibitory receptors&#xD;
      locally at the site where immune responses against melanoma proteins are stimulated by&#xD;
      vaccination, enhancing anti-melanoma immunity while avoiding the side-effects associated with&#xD;
      intravenous injection of these immune modulators. This is achieved by loading dendritic&#xD;
      cells, a type of immune cell, with RNA that encodes the immune modulator. The RNA-loaded&#xD;
      dendritic cells then make the immune modulatory proteins and release them locally. By mixing&#xD;
      these dendritic cells with additional dendritic cells loaded with melanoma proteins, the&#xD;
      immune modulators are released at the site where anti-melanoma immune cells are stimulated.&#xD;
&#xD;
      In this phase I trial, subjects with metastatic melanoma will undergo the process of&#xD;
      leukapheresis, in which white blood cells are removed from the body. Monocytes, a type of&#xD;
      immune cell, will then be purified from the white blood cells and cultured under conditions&#xD;
      that will change them into dendritic cells. Half of these dendritic cells are then loaded&#xD;
      with melanoma antigen RNA, which will lead to the production of melanoma antigen proteins&#xD;
      within the dendritic cells. The remaining half of the dendritic cells will be either&#xD;
      untreated or loaded with RNA encoding immune modulators so that these dendritic cells will&#xD;
      release immune modulators at the site of vaccination. These dendritic cells will be mixed&#xD;
      with the melanoma antigen-loaded dendritic cells and injected as a vaccine into lymph nodes.&#xD;
      Each subject will receive six weekly injections of their own dendritic cells. Safety and&#xD;
      toxicity will be closely monitored. In addition, immune responses against melanoma, as well&#xD;
      as clinical responses, will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of trials of immunotherapy in metastatic melanoma have clearly demonstrated that&#xD;
      immune responses against melanoma can be induced, but only a few patient have responded&#xD;
      clinically, suggesting that new strategies to enhance anti-cancer immune responses are&#xD;
      needed. Most of these immunotherapy trials have focused on antigen delivery and providing&#xD;
      stimulatory antigen-specific signals to T cells. However, the induction of antigen-specific T&#xD;
      cell-mediated immune responses is regulated not only by stimulatory signals, but also by&#xD;
      inhibitory receptor-mediated signals. Studies have demonstrated that administering mAbs&#xD;
      targeting such immune-modulating receptors on T cells enhances vaccine-induced anti-tumor&#xD;
      immunity, suggesting that such an approach might improve the efficacy of clinical cancer&#xD;
      vaccines. However, systemic administration such mAbs has been associated with severe,&#xD;
      sometimes fatal, autoimmunity. We have developed an approach for targeted delivery of such&#xD;
      immune modulatory proteins and mAbs, using immune modulator RNA-transfected dendritic cells&#xD;
      (DC), to sites where anti-tumor T cells are induced. Our preliminary studies indicate that&#xD;
      this approach may eliminate the adverse effects associated with systemic administration&#xD;
      immune modulators, while also enhancing vaccine-induced immune responses.&#xD;
&#xD;
      Therefore, the objective of this proposed Phase I immunotherapy trial is to determine the&#xD;
      safety and obtain preliminary data on the efficacy of vaccination of human subjects with&#xD;
      melanoma tumor associated antigen (TAA) RNA-transfected mature monocyte-derived DC&#xD;
      coadministered with additional untransfected DC (Study Arm A), DC transfected with RNA&#xD;
      encoding a soluble GITR-L fusion protein (Study Arm B), DC transfected with RNA encoding the&#xD;
      humanized heavy and light chains of an antagonistic anti-CTLA-4 mAb (Study Arm C), or DC&#xD;
      transfected with combined GITR-L and anti-CTLA-4 mAb RNA (Study Arm D). All study subjects&#xD;
      will undergo leukapheresis for collection of peripheral blood mononuclear cells (PBMC) and&#xD;
      purified monocytes will be cultured with the cytokines GM-CSF and IL-4 to produce immature&#xD;
      DC. After the induction maturation with a standard cytokine cocktail, half of the DC will&#xD;
      then be transfected with RNA encoding melanoma TAAs MART, tyrosinase, and gp100, and MAGE-3,&#xD;
      while the remaining half of the DC will be either untransfected (Study Arm A) or will be&#xD;
      transfected with immune modulator RNA (Study Arm B, C, and D). DC will be cryopreserved.&#xD;
      Subjects will then be immunized with these DC, weekly for six intranodal injections. For each&#xD;
      subject, safety and toxicity will be assessed, and anti-tumor immune responses will be&#xD;
      measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI retired&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>A minimum of 6 months</time_frame>
    <description>Safety and Tolerability will be assessed for all subjects during the vaccination period and then regularly during the post-vaccination period. All subjects will then be followed clinically as would be done any subject with melanoma for a total of 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular anti-melanoma immune responses will be assessed</measure>
    <time_frame>A minimum of 4 months</time_frame>
    <description>T cells from blood collected after each vaccination and following the full course of vaccination will be assessed for melanoma antigen-specificity using Interferon-gamma Elispot and cytotoxicity assays. Immune responses will be assessed following each vaccination and then will continue to be assessed until anti-melanoma immune responses return to baseline levels.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Vaccine plus untransfected DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine plus GITRL RNA DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine plus antiCTLA4 RNA DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine plus GITRL/ antiCTLA4 RNA DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with RNA-transfected mature autologous DC</intervention_name>
    <description>Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals</description>
    <arm_group_label>Vaccine plus GITRL RNA DC</arm_group_label>
    <arm_group_label>Vaccine plus GITRL/ antiCTLA4 RNA DC</arm_group_label>
    <arm_group_label>Vaccine plus antiCTLA4 RNA DC</arm_group_label>
    <arm_group_label>Vaccine plus untransfected DC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed metastatic melanoma&#xD;
&#xD;
          -  Karnofsky performance status greater than or equal to 70%.&#xD;
&#xD;
          -  Estimated life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Age &gt; 17 years.&#xD;
&#xD;
          -  Adequate hematologic function with:&#xD;
&#xD;
               -  WBC &gt;= 3000 mm3&#xD;
&#xD;
               -  hemoglobin &gt;= 9 mg/dl&#xD;
&#xD;
               -  platelets &gt;= 100,000/mm3&#xD;
&#xD;
          -  Adequate renal and hepatic function with:&#xD;
&#xD;
               -  serum creatinine &lt; 2.5 mg/dl&#xD;
&#xD;
               -  bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
               -  AST/SGOT &lt; 70 U/L&#xD;
&#xD;
               -  ALT/SGPT &lt; 70 U/L&#xD;
&#xD;
               -  Alkaline Phosphatase â‰¤ 135 U/L&#xD;
&#xD;
          -  Ability to understand and provide signed informed consent that fulfills Institutional&#xD;
             Review Board guidelines.&#xD;
&#xD;
          -  Ability to return to Duke University Medical Center for adequate follow-up as required&#xD;
             by this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects undergoing concurrent chemotherapy, radiation therapy, or immunotherapy will&#xD;
             be excluded.&#xD;
&#xD;
          -  The subject has previously irradiated, surgically treated, or newly diagnosed central&#xD;
             nervous system (CNS) metastases will be excluded (Pre-enrollment head CT is not&#xD;
             required if not indicated by clinical signs or symptoms).&#xD;
&#xD;
          -  Subjects with a history of autoimmune disease such as, but not restricted to,&#xD;
             inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis,&#xD;
             scleroderma, or multiple sclerosis will be excluded.&#xD;
&#xD;
          -  Subjects with serious concurrent chronic or acute illness such as pulmonary (asthma or&#xD;
             COPD), cardiac (NYHA class III or IV) or hepatic disease, or other illness considered&#xD;
             by the principal investigator to constitute an unwarranted high risk for&#xD;
             investigational drug administration will be excluded.&#xD;
&#xD;
          -  Subjects with medical or psychological impediment to probable compliance with the&#xD;
             protocol will be excluded.&#xD;
&#xD;
          -  Subjects with concurrent second malignancy other than melanoma or non-melanoma skin&#xD;
             cancer will be excluded. In the event of prior non-melanoma malignancies treated&#xD;
             surgically, the subject must be considered NED (no evidence of disease) for a minimum&#xD;
             of 3 years prior to enrollment.&#xD;
&#xD;
          -  Presence of an active acute or chronic infection, including symptomatic urinary tract&#xD;
             infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral&#xD;
             hepatitis (as determined by HBsAg and Hepatitis C serology) will lead to subject&#xD;
             exclusion.&#xD;
&#xD;
          -  Subjects receiving steroid therapy (or other immunosuppressive agents such as&#xD;
             azathioprine or cyclosporine A) are excluded on the basis of potential immune&#xD;
             suppression.&#xD;
&#xD;
          -  Subjects with inadequate peripheral vein access to undergo leukapheresis will be&#xD;
             excluded.&#xD;
&#xD;
          -  Female subjects with a positive pregnancy test, as well as those who have not&#xD;
             previously undergone hysterectomy and/or bilateral oophorectomy and are unwilling to&#xD;
             utilize a medically approved form of contraception, from the time of enrollment until&#xD;
             6 weeks after the final immunization, will be excluded.&#xD;
&#xD;
          -  Male subjects, not previously surgically sterilized, who are unwilling to use a condom&#xD;
             with spermicide during any sexual activity occurring over the entire immunization&#xD;
             period and for the 6 weeks that immediately follow the final immunization will be&#xD;
             excluded.&#xD;
&#xD;
          -  Subjects with a documented history of severe allergic reaction to beta-lactams, eggs&#xD;
             or soy products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott K Pruitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol. 2011 Dec;41(12):3553-63. doi: 10.1002/eji.201141383. Epub 2011 Oct 26.</citation>
    <PMID>22028176</PMID>
  </reference>
  <reference>
    <citation>Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 2009 Dec;16(12):900-11. doi: 10.1038/cgt.2009.39. Epub 2009 Jun 5.</citation>
    <PMID>19498460</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>dendritic cell</keyword>
  <keyword>GITR-ligand</keyword>
  <keyword>CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

